{"gene":"PDCD1","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2008,"finding":"PD-1 delivers inhibitory signals by interacting with its ligands PD-L1 and PD-L2; additionally, B7-1 was identified as a binding partner for PD-L1, revealing an inhibitory bidirectional interaction between PD-L1 and B7-1 that regulates T cell activation and tolerance.","method":"Binding partner identification; functional immunological assays in T cells and mouse models","journal":"Annual review of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — findings independently replicated across multiple labs and summarized across extensive experimental work including co-receptor binding and mouse knockout models","pmids":["18173375"],"is_preprint":false},{"year":2007,"finding":"PD-1 negatively regulates antigen receptor signaling by recruiting the protein tyrosine phosphatase SHP-2 upon interacting with either PD-L1 or PD-L2.","method":"Biochemical signaling assays; phosphatase recruitment studies","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — SHP-2 recruitment mechanism replicated across multiple labs; mechanistic consensus in the field","pmids":["17606980"],"is_preprint":false},{"year":2017,"finding":"Tumour-associated macrophages (TAMs) express PD-1, and PD-1 expression on TAMs correlates negatively with phagocytic potency against tumour cells. Blockade of PD-1/PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth, and lengthens survival in mouse cancer models in a macrophage-dependent fashion.","method":"Flow cytometry of mouse and human TAMs; in vivo PD-1/PD-L1 blockade in mouse cancer models; macrophage depletion experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in mouse and human samples with macrophage-specific depletion validation","pmids":["28514441"],"is_preprint":false},{"year":2020,"finding":"PD-1 is extensively N-glycosylated in T cells; glycosylation is critical for PD-1 protein stability and cell surface localization. Glycosylation at the N58 site is essential for mediating PD-1 interaction with PD-L1. TCR activation alters the intensities of specific PD-1 glycoforms.","method":"Glycosylation assays; mutagenesis of N-glycosylation sites (N58 and others); cell surface localization studies; PD-L1 binding assays with glycosylation-deficient PD-1","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of specific glycosylation sites combined with binding assays and localization studies in a single study; independently corroborated by EMBO Reports paper (PMID 33063473)","pmids":["32156778","33063473"],"is_preprint":false},{"year":2020,"finding":"N-glycosylation of asparagine 58 (N58) of PD-1 promotes the interaction with the anti-PD-1 antibody camrelizumab. Crystal structure of the camrelizumab/PD-1 complex shows camrelizumab primarily uses its heavy chain to bind PD-1 while the light chain sterically inhibits PD-L1 binding. Non-glycosylated PD-1 shows substantially decreased binding affinity for camrelizumab.","method":"Crystal structure of camrelizumab/PD-1 complex; binding affinity assays with glycosylated vs. non-glycosylated PD-1; N-glycan composition analysis","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional validation (binding assays), single lab but multiple orthogonal approaches","pmids":["33063473"],"is_preprint":false},{"year":2021,"finding":"PD-1 signaling suppresses TCR-CD8 cooperativity during T cell antigen recognition: PD-1/PD-L1 engagement results in smaller T cell spreading area, fewer molecular bonds formed, and shorter bond lifetimes of T cell interaction with peptide-MHC, in a manner dependent on SHP phosphatases and Leukocyte C-terminal Src kinase (Lck). PD-1 disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction and prevents CD8 from augmenting antigen recognition.","method":"Biophysical force measurements; quantitative imaging of T cell-pMHC interactions; SHP inhibition and Lck perturbation experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biophysical reconstitution with multiple orthogonal methods including force measurements and pharmacological dissection of SHP/Lck dependence","pmids":["33980853"],"is_preprint":false},{"year":2024,"finding":"PD-1 and its ligands form dimers as a consequence of transmembrane domain interactions. Propensity for dimerization correlates with the ability of PD-1 to inhibit immune responses, antitumor immunity, cytotoxic T cell function, and autoimmune tissue destruction.","method":"Biochemical dimerization assays; transmembrane domain mutational analysis; functional T cell assays; in vivo mouse models of antitumor immunity and autoimmunity","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — transmembrane domain mutagenesis linked to functional outcomes in multiple experimental systems","pmids":["38457513"],"is_preprint":false},{"year":2023,"finding":"USP5 is a deubiquitinase for PD-1 that interacts with PD-1 and promotes its deubiquitination and stabilization. ERK phosphorylates PD-1 at Thr234, which promotes PD-1 interaction with USP5. Conditional T cell-specific knockout of Usp5 increases effector cytokine production and retards tumor growth in mice.","method":"Co-immunoprecipitation; ubiquitination assays; phosphorylation site mutagenesis (Thr234); conditional Usp5 knockout mice; in vivo tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, in vitro ubiquitination/deubiquitination assays, site-directed mutagenesis, and in vivo KO with defined phenotype in a single study","pmids":["37208329"],"is_preprint":false},{"year":2020,"finding":"KLHL22, an adaptor of the Cul3-based E3 ubiquitin ligase, is a major PD-1-associated protein that mediates ubiquitination and degradation of PD-1 before its transport to the cell surface. KLHL22 deficiency leads to overaccumulation of PD-1, suppressing antitumor T cell responses.","method":"Co-immunoprecipitation; ubiquitination assays; KLHL22 knockout/knockdown; flow cytometry of surface PD-1; in vivo tumor models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay, KO with surface localization and tumor phenotype readouts","pmids":["33109719"],"is_preprint":false},{"year":2015,"finding":"NF-κB regulates PD-1 expression in macrophages. An NF-κB binding site located upstream of the PDCD1 gene in conserved region C is required for NF-κB-dependent PD-1 gene activation in macrophages stimulated with LPS. Chromatin immunoprecipitation showed NF-κB p65 binding to this region. In CD4 T cells, PD-1 induction requires NFAT (blocked by cyclosporin A); in macrophages, LPS-induced PD-1 expression is cyclosporin A-insensitive.","method":"NF-κB binding site deletion/mutagenesis; chromatin immunoprecipitation (ChIP); cyclosporin A pharmacological inhibition; stimulation of primary macrophages and T cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — promoter mutagenesis combined with ChIP and pharmacological dissection of signaling pathways","pmids":["25810391"],"is_preprint":false},{"year":2014,"finding":"PD-1 engagement by its ligands inhibits T cell proliferation, cytokine production, and cytolytic function by inhibiting membrane-proximal T cell signaling events, in a mechanism distinct from CTLA-4 (which targets more downstream signaling pathways). PD-1 ligation inhibits TCR proximal signaling via phosphatase recruitment.","method":"Primary T cell signaling assays; pharmacological inhibition; comparison with CTLA-4 signaling","journal":"Cancer journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — review summarizing signaling data from primary T cells; single lab perspective without direct experimental novelty reported in this paper","pmids":["25098287"],"is_preprint":false},{"year":2014,"finding":"PD-1 is dispensable for thymic T regulatory (Treg) cell development and suppressive function, but is critical for extrathymic differentiation of peripherally induced Treg (pTreg) cells in vivo. In PD-1-deficient mice, conventional CD4+ T cells showed markedly diminished differentiation into pTreg cells across three different in vivo experimental settings.","method":"PD-1-deficient mice; in vivo and in vitro Treg differentiation assays; suppression assays with PD-1−/− Tregs","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — PD-1 KO mice with multiple independent in vivo experimental settings and in vitro functional assays","pmids":["24975127"],"is_preprint":false},{"year":2021,"finding":"In a patient with inherited complete PD-1 deficiency, leukocytes did not express PD-1 or respond to PD-1-mediated suppression. The patient had depletion of Vδ2+ γδ T, mucosal-associated invariant T (MAIT), and CD56bright NK lymphocytes, with other T cell dysfunction resulting in reduced IFN-γ production upon mycobacterial stimuli and susceptibility to tuberculosis. Expansion of RORγT+ CD4-CD8- double-negative αβ T cells driven by excessive STAT3-activating cytokines (IL-6, IL-23) led to lymphoproliferative autoimmunity.","method":"Human genetics (inherited PDCD1 loss-of-function); immunophenotyping; functional T cell assays; cytokine measurement; transcription factor analysis","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human inborn error of immunity with comprehensive mechanistic characterization across multiple immune lineages","pmids":["34183838"],"is_preprint":false},{"year":2019,"finding":"MATR3 is a splicing activator for PDCD1 exon 3 splicing, operating through binding to the ESE3b splicing enhancer in exon 3. MATR3's splicing-stimulatory activity is counteracted by an RNA secondary structure around ESE3b and an RNA helicase DDX5. Two splicing enhancers (ESE3a and ESE3b) in exon 3 regulate alternative splicing of PDCD1 to generate the exon 3-skipped isoform PD-1Δ3.","method":"Minigene splicing assays; deletion analysis; mutagenesis; RNA-affinity chromatography; mass spectrometry; MATR3 depletion and overexpression","journal":"RNA biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution (RNA affinity chromatography), mutagenesis, MS identification of binding proteins, and functional splicing assays","pmids":["31441370"],"is_preprint":false},{"year":2024,"finding":"In obesity, type I inflammatory cytokines and obesity-linked molecules (IFN-γ, TNF, leptin, insulin, palmitate) induce macrophage PD-1 expression in an mTORC1- and glycolysis-dependent manner. PD-1 then provides negative feedback to TAMs, suppressing glycolysis, phagocytosis, and T cell stimulatory potential. Myeloid-specific PD-1 deficiency slows tumor growth, enhances TAM glycolysis and antigen-presentation, and increases CD8+ T cell activity.","method":"In vitro macrophage stimulation assays; mTORC1 inhibition; myeloid-specific PD-1 KO mice; glycolysis measurements; flow cytometry of MHC/CD86 expression and T cell activation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Moderate — myeloid-specific KO with multiple mechanistic readouts (glycolysis, phagocytosis, antigen presentation) and pharmacological dissection of mTORC1 pathway","pmids":["38867043"],"is_preprint":false},{"year":2023,"finding":"PD-1 maintains peripheral CD8 T cell tolerance in skin by preventing tissue-infiltrating antigen-specific effector CD8 T cells from acquiring a fully pathogenic differentiation state, secreting effector molecules, and gaining access to epidermal antigen-expressing cells. In the absence of PD-1, epidermal antigen-expressing cells were eliminated by CD8 T cells, causing local pathology.","method":"Mouse model with skin-specific T cell antigen expression; PD-1 KO; transcriptomic analysis; CD8 T cell functional assays; analysis of human skin biopsies from lichenoid irAE patients","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mouse genetic model with defined antigen specificity and PD-1 KO, validated with human clinical biopsy transcriptomics","pmids":["37344588"],"is_preprint":false},{"year":2022,"finding":"PD-1 signaling in podocytes contributes to kidney aging: increased PD-1 expression in aged podocytes promotes a senescence-associated secretory phenotype (SASP) and reduces cell survival in vitro. Anti-PD-1 antibody treatment in aged mice improved the aging phenotype in kidney and liver, specifically extending podocyte lifespan in the glomerulus.","method":"In vitro podocyte PD-1 signaling assays; anti-PD-1 antibody treatment of aged mice; transcriptomic and immunohistochemistry studies; focal segmental glomerulosclerosis (FSGS) mouse model","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic studies plus in vivo KO/blockade in two independent mouse models; non-canonical cell type (podocytes)","pmids":["35968783"],"is_preprint":false},{"year":2022,"finding":"PD-L1+ senescent cells are resistant to CD8+ T cell immune surveillance, whereas PD-L1- senescent cells are sensitive. PD-1 antibody administration to naturally ageing or NASH-model mice reduces total p16+ senescent cells and the PD-L1+ senescent cell population in an activated CD8+ T cell-dependent manner.","method":"Single-cell analysis of p16+ cells in vivo; PD-1 antibody treatment of aged and disease mouse models; CD8+ T cell depletion experiments; flow cytometry","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — CD8+ T cell depletion epistasis experiment establishes mechanism; replicated in multiple in vivo models","pmids":["36323784"],"is_preprint":false},{"year":2016,"finding":"A proliferative CD8+ T cell subset that responds to PD-1 blockade during chronic LCMV infection is characterized by PD-1 expression alongside costimulatory molecules (ICOS, CD28), a TCF1-dependent gene signature related to memory precursors and stem cells, and exclusive residence in lymphoid tissue T cell zones. This subset undergoes self-renewal and differentiates into terminally exhausted CD8+ T cells. TCF1 has a cell-intrinsic and essential role in generating this subset.","method":"Mouse chronic LCMV infection model; PD-1 blockade; transcriptomic profiling; TCF1-deficient mice; cell fate tracking; tissue localization studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — TCF1 genetic KO with cell fate tracking and transcriptomics in a well-controlled chronic infection model","pmids":["27501248"],"is_preprint":false},{"year":2014,"finding":"Pre-existing CD8+ T cells at the invasive tumor margin that express PD-1, in close proximity to PD-L1-expressing cells, predict response to anti-PD-1 therapy. Responding patients showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic tumor reduction, consistent with PD-1/PD-L1-mediated adaptive immune resistance as the mechanism of suppression.","method":"Quantitative immunohistochemistry; quantitative multiplex immunofluorescence; next-generation TCR sequencing; serial tumor biopsies before and during pembrolizumab therapy","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — correlative tissue analysis in human patients with serial biopsies; consistent with mechanism but observational rather than experimental","pmids":["25428505"],"is_preprint":false}],"current_model":"PD-1 (PDCD1) is an inducible inhibitory receptor on T cells (and other immune cells including macrophages) that, upon engagement by PD-L1 or PD-L2, recruits the tyrosine phosphatase SHP-2 to dephosphorylate proximal TCR signaling components, disrupts cooperative TCR-pMHC-CD8 trimolecular antigen recognition, suppresses T cell proliferation/cytokine production/cytolysis, and promotes peripheral tolerance; its surface expression and stability are regulated by N-glycosylation (critical for PD-L1 binding at N58), ubiquitination/deubiquitination (via KLHL22/Cul3 E3 ligase for degradation and USP5 deubiquitinase for stabilization downstream of ERK-mediated Thr234 phosphorylation), NF-κB- and NFAT-dependent transcription, and alternative splicing (regulated by MATR3/ESE3b); PD-1 also forms functional transmembrane dimers whose dimerization propensity correlates with inhibitory potency, and beyond T cells, PD-1 on macrophages suppresses phagocytosis and antigen presentation via mTORC1/glycolysis-dependent feedback, while PD-1 on podocytes drives senescence-associated phenotypes during kidney aging."},"narrative":{"mechanistic_narrative":"PDCD1 (PD-1) is an inducible inhibitory immune receptor that, upon engagement by its ligands PD-L1 and PD-L2, restrains antigen-receptor signaling to enforce peripheral tolerance and limit antiretumor and antimicrobial immunity [PMID:18173375, PMID:25098287]. Mechanistically, ligand-bound PD-1 recruits the tyrosine phosphatase SHP-2 to dephosphorylate membrane-proximal TCR signaling components, thereby inhibiting T cell proliferation, cytokine production, and cytolytic function in a manner distinct from CTLA-4 [PMID:17606980, PMID:25098287]; biophysically, this disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction, reducing T cell spreading and bond lifetimes in an SHP- and Lck-dependent fashion [PMID:33980853]. PD-1 surface expression and signaling output are tightly tuned: transcription is driven by NFAT in CD4 T cells and by NF-κB in macrophages [PMID:25810391]; N-glycosylation, particularly at N58, controls protein stability, surface localization, and PD-L1 binding [PMID:32156778, PMID:33063473]; and surface abundance is set by competing ubiquitination via the KLHL22/Cul3 E3 ligase that degrades PD-1 before surface transport and deubiquitination/stabilization by USP5 downstream of ERK-mediated Thr234 phosphorylation [PMID:37208329, PMID:33109719]. PD-1 also forms transmembrane-domain-mediated dimers whose dimerization propensity correlates with inhibitory potency [PMID:38457513], and its exon 3 alternative splicing is governed by MATR3 acting through the ESE3b enhancer [PMID:31441370]. Physiologically, PD-1 supports peripheral induced Treg differentiation and CD8 T cell tolerance in tissues such as skin [PMID:24975127, PMID:37344588], and shapes the TCF1-dependent stem-like CD8 T cell subset that responds to PD-1 blockade during chronic infection [PMID:27501248]. Inherited complete PD-1 deficiency in humans causes multilineage lymphocyte dysfunction, susceptibility to tuberculosis, and STAT3-cytokine-driven lymphoproliferative autoimmunity, establishing its non-redundant tolerogenic role [PMID:34183838]. Beyond T cells, PD-1 is expressed on tumor-associated macrophages where it suppresses phagocytosis, glycolysis, and antigen presentation through mTORC1-dependent feedback [PMID:28514441, PMID:38867043], and on aged podocytes where it drives senescence-associated phenotypes [PMID:35968783].","teleology":[{"year":2007,"claim":"Established the proximal biochemical mechanism of PD-1 inhibition by showing ligand engagement recruits the phosphatase SHP-2 to antigen-receptor signaling machinery.","evidence":"Biochemical phosphatase recruitment assays following PD-L1/PD-L2 engagement","pmids":["17606980"],"confidence":"High","gaps":["Did not resolve which TCR substrates are dephosphorylated","SHP-1 versus SHP-2 contributions not delineated here"]},{"year":2008,"claim":"Defined the receptor-ligand topology of the pathway, identifying PD-L1 and PD-L2 as PD-1 ligands and an additional inhibitory PD-L1/B7-1 axis regulating tolerance.","evidence":"Binding partner identification and functional immunological assays in T cells and mouse models","pmids":["18173375"],"confidence":"High","gaps":["Relative in vivo contribution of each ligand interaction not quantified","Does not address cell-type-specific ligand usage"]},{"year":2014,"claim":"Distinguished PD-1 from CTLA-4 mechanistically by localizing PD-1 inhibition to membrane-proximal TCR events, and defined PD-1 as required for peripheral but not thymic Treg differentiation.","evidence":"Primary T cell signaling assays and PD-1-deficient mouse Treg differentiation/suppression assays","pmids":["25098287","24975127"],"confidence":"Medium","gaps":["Signaling comparison drawn from review-level synthesis","Molecular link between PD-1 signaling and pTreg fate not defined"]},{"year":2015,"claim":"Resolved cell-type-specific transcriptional control of PDCD1, showing NF-κB drives macrophage expression while NFAT drives T cell induction.","evidence":"Promoter mutagenesis, ChIP for NF-κB p65, and cyclosporin A dissection in primary macrophages and T cells","pmids":["25810391"],"confidence":"High","gaps":["Full set of regulatory elements not mapped","Does not address chromatin state or enhancer dynamics during exhaustion"]},{"year":2016,"claim":"Identified the cellular target of PD-1 blockade as a TCF1-dependent stem-like CD8 T cell subset that self-renews and seeds terminally exhausted cells.","evidence":"Chronic LCMV mouse model, PD-1 blockade, transcriptomics, TCF1-deficient mice, and cell fate tracking","pmids":["27501248"],"confidence":"High","gaps":["Direct molecular signaling from PD-1 to TCF1 program not established","Human correlate not tested in this study"]},{"year":2017,"claim":"Extended PD-1 function beyond T cells by demonstrating macrophage PD-1 restrains tumor-cell phagocytosis, with blockade acting in a macrophage-dependent manner.","evidence":"Flow cytometry of mouse/human TAMs, in vivo PD-1/PD-L1 blockade, and macrophage depletion","pmids":["28514441"],"confidence":"High","gaps":["Signaling pathway downstream of macrophage PD-1 not defined in this study","Does not separate direct macrophage effect from T cell crosstalk fully"]},{"year":2019,"claim":"Uncovered post-transcriptional control of PD-1 by defining MATR3 as a splicing activator for PDCD1 exon 3 acting through the ESE3b enhancer, counteracted by RNA structure and DDX5.","evidence":"Minigene splicing assays, RNA-affinity chromatography, mass spectrometry, and MATR3 depletion/overexpression","pmids":["31441370"],"confidence":"High","gaps":["Functional consequence of the PD-1Δ3 isoform in vivo not established","Physiological signals that tune splicing not identified"]},{"year":2020,"claim":"Established that N-glycosylation controls PD-1 stability, surface localization, and ligand/antibody binding, with N58 critical for PD-L1 and camrelizumab engagement.","evidence":"Glycosylation-site mutagenesis, binding assays, surface localization studies, and a camrelizumab/PD-1 crystal structure","pmids":["32156778","33063473"],"confidence":"High","gaps":["Enzymes generating specific glycoforms not identified","Link between TCR-induced glycoform changes and inhibitory output not quantified"]},{"year":2020,"claim":"Defined a degradative arm of PD-1 surface control, showing the KLHL22/Cul3 E3 ligase ubiquitinates PD-1 before surface transport to limit its accumulation.","evidence":"Co-IP, ubiquitination assays, KLHL22 knockout/knockdown, surface PD-1 flow cytometry, and tumor models","pmids":["33109719"],"confidence":"High","gaps":["Subcellular site of ubiquitination not precisely localized","Signals regulating KLHL22 activity unknown"]},{"year":2021,"claim":"Provided biophysical mechanism showing PD-1 disrupts cooperative TCR-pMHC-CD8 trimolecular antigen recognition in an SHP- and Lck-dependent manner.","evidence":"Biophysical force measurements, quantitative imaging of T cell-pMHC interactions, and SHP/Lck perturbation","pmids":["33980853"],"confidence":"High","gaps":["Direct phosphatase substrate at the CD8 coreceptor not identified","In vivo relevance of altered bond lifetimes not measured"]},{"year":2021,"claim":"Demonstrated the non-redundant human role of PD-1 through an inherited complete deficiency causing multilineage lymphocyte loss, tuberculosis susceptibility, and STAT3-cytokine-driven autoimmunity.","evidence":"Human genetics of PDCD1 loss-of-function with immunophenotyping, functional T cell and cytokine assays","pmids":["34183838"],"confidence":"High","gaps":["Single-patient inborn error limits generalization","Mechanistic basis for selective lineage depletion not fully resolved"]},{"year":2022,"claim":"Connected PD-1 to senescence biology, showing PD-L1+ senescent cells evade CD8 surveillance and PD-1 blockade clears senescent cells, while PD-1 in podocytes drives senescence-associated phenotypes during aging.","evidence":"Single-cell p16 analysis with CD8 depletion epistasis; in vitro podocyte signaling plus anti-PD-1 treatment in aged/FSGS mouse models","pmids":["36323784","35968783"],"confidence":"Medium","gaps":["Podocyte-intrinsic PD-1 signaling pathway not fully defined","Whether senescent-cell clearance is purely T cell-extrinsic to podocyte PD-1 unresolved"]},{"year":2023,"claim":"Showed PD-1 enforces tissue tolerance by preventing antigen-specific effector CD8 T cells from acquiring a fully pathogenic state in skin, with human irAE relevance.","evidence":"Skin-antigen mouse model with PD-1 KO, transcriptomics, CD8 functional assays, and human lichenoid irAE biopsy transcriptomics","pmids":["37344588"],"confidence":"High","gaps":["Molecular checkpoint within the differentiation trajectory not pinpointed","Generalizability to non-skin tissues not tested"]},{"year":2023,"claim":"Identified a stabilizing arm of PD-1 abundance control, showing ERK-mediated Thr234 phosphorylation recruits USP5 to deubiquitinate and stabilize PD-1.","evidence":"Reciprocal Co-IP, ubiquitination assays, Thr234 mutagenesis, and T cell-specific Usp5 knockout tumor models","pmids":["37208329"],"confidence":"High","gaps":["Interplay between USP5 stabilization and KLHL22 degradation not integrated","Upstream triggers of ERK-Thr234 phosphorylation not defined"]},{"year":2024,"claim":"Defined PD-1 dimerization and macrophage metabolic feedback as determinants of inhibitory potency, linking transmembrane-domain dimerization to function and mTORC1/glycolysis to macrophage PD-1 induction.","evidence":"Transmembrane-domain mutagenesis with functional T cell/tumor/autoimmunity assays; macrophage stimulation, mTORC1 inhibition, and myeloid-specific PD-1 KO with glycolysis/antigen-presentation readouts","pmids":["38457513","38867043"],"confidence":"High","gaps":["Structural basis of dimer assembly not solved","How dimerization mechanistically amplifies SHP recruitment not shown"]},{"year":null,"claim":"How the competing ubiquitination/deubiquitination, glycosylation, dimerization, and splicing inputs are integrated to set PD-1 inhibitory output in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model linking surface-abundance control to signaling strength","Non-T-cell PD-1 signaling cascades (macrophage, podocyte) incompletely mapped","Direct phosphatase substrate set not fully enumerated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,10,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,10]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,8,6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,10,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,5,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,7,8]}],"complexes":[],"partners":["CD274","PDCD1LG2","PTPN11","USP5","KLHL22","MATR3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15116","full_name":"Programmed cell death protein 1","aliases":[],"length_aa":288,"mass_kda":31.6,"function":"Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005, PubMed:31754127, PubMed:32184441, PubMed:37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005, PubMed:26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed:32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed:32184441) The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:22658127, PubMed:25034862, PubMed:25399552)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q15116/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDCD1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDCD1","total_profiled":1310},"omim":[{"mim_id":"621235","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 5; ADMIO5","url":"https://www.omim.org/entry/621235"},{"mim_id":"621234","title":"ICHAD SYNDROME; ICHAD","url":"https://www.omim.org/entry/621234"},{"mim_id":"621004","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 4; ADMIO4","url":"https://www.omim.org/entry/621004"},{"mim_id":"618534","title":"IMMUNODEFICIENCY 64 WITH LYMPHOPROLIFERATION; IMD64","url":"https://www.omim.org/entry/618534"},{"mim_id":"615952","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1; ADMIO1","url":"https://www.omim.org/entry/615952"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"heart muscle","ntpm":6.4},{"tissue":"lymphoid tissue","ntpm":15.0}],"url":"https://www.proteinatlas.org/search/PDCD1"},"hgnc":{"alias_symbol":["CD279","PD1","hSLE1","PD-1"],"prev_symbol":["SLEB2"]},"alphafold":{"accession":"Q15116","domains":[{"cath_id":"2.60.40.10","chopping":"37-144","consensus_level":"high","plddt":92.4791,"start":37,"end":144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15116","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15116-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15116-F1-predicted_aligned_error_v6.png","plddt_mean":74.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDCD1","jax_strain_url":"https://www.jax.org/strain/search?query=PDCD1"},"sequence":{"accession":"Q15116","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15116.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15116/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15116"}},"corpus_meta":[{"pmid":"26028255","id":"PMC_26028255","title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.","date":"2015","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26028255","citation_count":7570,"is_preprint":false},{"pmid":"25428505","id":"PMC_25428505","title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25428505","citation_count":5468,"is_preprint":false},{"pmid":"18173375","id":"PMC_18173375","title":"PD-1 and its ligands in tolerance and immunity.","date":"2008","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18173375","citation_count":4373,"is_preprint":false},{"pmid":"23724846","id":"PMC_23724846","title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23724846","citation_count":2788,"is_preprint":false},{"pmid":"27433843","id":"PMC_27433843","title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27433843","citation_count":2573,"is_preprint":false},{"pmid":"26997480","id":"PMC_26997480","title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26997480","citation_count":2522,"is_preprint":false},{"pmid":"20636820","id":"PMC_20636820","title":"The PD-1 pathway in tolerance and autoimmunity.","date":"2010","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20636820","citation_count":1869,"is_preprint":false},{"pmid":"28514441","id":"PMC_28514441","title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514441","citation_count":1818,"is_preprint":false},{"pmid":"27501248","id":"PMC_27501248","title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27501248","citation_count":1703,"is_preprint":false},{"pmid":"29658848","id":"PMC_29658848","title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.","date":"2018","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29658848","citation_count":1626,"is_preprint":false},{"pmid":"27903500","id":"PMC_27903500","title":"Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.","date":"2016","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27903500","citation_count":1092,"is_preprint":false},{"pmid":"17606980","id":"PMC_17606980","title":"PD-1 and PD-1 ligands: from discovery to clinical application.","date":"2007","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17606980","citation_count":1028,"is_preprint":false},{"pmid":"19426218","id":"PMC_19426218","title":"PD-1 signaling in primary T cells.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426218","citation_count":630,"is_preprint":false},{"pmid":"38762484","id":"PMC_38762484","title":"Regulatory mechanisms of PD-1/PD-L1 in cancers.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38762484","citation_count":552,"is_preprint":false},{"pmid":"28376884","id":"PMC_28376884","title":"Cancer immunotherapies targeting the PD-1 signaling pathway.","date":"2017","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/28376884","citation_count":506,"is_preprint":false},{"pmid":"26047524","id":"PMC_26047524","title":"PD-1/PD-L1 inhibitors.","date":"2015","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26047524","citation_count":454,"is_preprint":false},{"pmid":"32948597","id":"PMC_32948597","title":"Revisiting the PD-1 pathway.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32948597","citation_count":418,"is_preprint":false},{"pmid":"31205619","id":"PMC_31205619","title":"Application of PD-1 Blockade in Cancer Immunotherapy.","date":"2019","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/31205619","citation_count":399,"is_preprint":false},{"pmid":"36323784","id":"PMC_36323784","title":"Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36323784","citation_count":360,"is_preprint":false},{"pmid":"22900886","id":"PMC_22900886","title":"Role of the PD-1 pathway in the immune response.","date":"2012","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/22900886","citation_count":358,"is_preprint":false},{"pmid":"17433872","id":"PMC_17433872","title":"PD-1 and its ligands in T-cell immunity.","date":"2007","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17433872","citation_count":349,"is_preprint":false},{"pmid":"32036071","id":"PMC_32036071","title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.","date":"2020","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32036071","citation_count":347,"is_preprint":false},{"pmid":"25701325","id":"PMC_25701325","title":"PD-1 Restrains Radiotherapy-Induced Abscopal Effect.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25701325","citation_count":323,"is_preprint":false},{"pmid":"21276005","id":"PMC_21276005","title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance.","date":"2011","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21276005","citation_count":275,"is_preprint":false},{"pmid":"32364844","id":"PMC_32364844","title":"PD-1 Blockade in Anaplastic Thyroid Carcinoma.","date":"2020","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32364844","citation_count":257,"is_preprint":false},{"pmid":"27974689","id":"PMC_27974689","title":"PD-1 and its ligands are important immune checkpoints in cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27974689","citation_count":254,"is_preprint":false},{"pmid":"32265932","id":"PMC_32265932","title":"The Role of PD-1 in Acute and Chronic Infection.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32265932","citation_count":252,"is_preprint":false},{"pmid":"33854633","id":"PMC_33854633","title":"A snapshot of the PD-1/PD-L1 pathway.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33854633","citation_count":226,"is_preprint":false},{"pmid":"27660198","id":"PMC_27660198","title":"PD-1/PD-L and autoimmunity: A growing relationship.","date":"2016","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27660198","citation_count":225,"is_preprint":false},{"pmid":"26945088","id":"PMC_26945088","title":"Genetic and Epigenetic Regulation of PD-1 Expression.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26945088","citation_count":196,"is_preprint":false},{"pmid":"31661771","id":"PMC_31661771","title":"PD-L1/PD-1 Axis in Glioblastoma Multiforme.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31661771","citation_count":164,"is_preprint":false},{"pmid":"28929192","id":"PMC_28929192","title":"Role of PD-1 in Immunity and Diseases.","date":"2017","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28929192","citation_count":162,"is_preprint":false},{"pmid":"30063143","id":"PMC_30063143","title":"Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.","date":"2018","source":"Nano letters","url":"https://pubmed.ncbi.nlm.nih.gov/30063143","citation_count":157,"is_preprint":false},{"pmid":"35228677","id":"PMC_35228677","title":"Biomarkers of response to PD-1 pathway blockade.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35228677","citation_count":154,"is_preprint":false},{"pmid":"25798726","id":"PMC_25798726","title":"Nivolumab: targeting PD-1 to bolster antitumor immunity.","date":"2015","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25798726","citation_count":154,"is_preprint":false},{"pmid":"34006473","id":"PMC_34006473","title":"Emerging concepts in PD-1 checkpoint biology.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34006473","citation_count":152,"is_preprint":false},{"pmid":"25098287","id":"PMC_25098287","title":"Biochemical signaling of PD-1 on T cells and its functional implications.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/25098287","citation_count":152,"is_preprint":false},{"pmid":"31644329","id":"PMC_31644329","title":"PD-1 Blockade in Advanced Adrenocortical Carcinoma.","date":"2019","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31644329","citation_count":151,"is_preprint":false},{"pmid":"26162965","id":"PMC_26162965","title":"New immunotherapies targeting the PD-1 pathway.","date":"2015","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26162965","citation_count":145,"is_preprint":false},{"pmid":"28346916","id":"PMC_28346916","title":"PD-1/PD-L1 Pathway in Breast Cancer.","date":"2017","source":"Oncology research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/28346916","citation_count":144,"is_preprint":false},{"pmid":"25810391","id":"PMC_25810391","title":"NF-κB regulates PD-1 expression in macrophages.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25810391","citation_count":144,"is_preprint":false},{"pmid":"32156778","id":"PMC_32156778","title":"Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32156778","citation_count":139,"is_preprint":false},{"pmid":"38867043","id":"PMC_38867043","title":"Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38867043","citation_count":129,"is_preprint":false},{"pmid":"34368780","id":"PMC_34368780","title":"PAK4 inhibition improves PD-1 blockade immunotherapy.","date":"2019","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34368780","citation_count":127,"is_preprint":false},{"pmid":"28642997","id":"PMC_28642997","title":"PD-1 and cancer: molecular mechanisms and polymorphisms.","date":"2017","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28642997","citation_count":122,"is_preprint":false},{"pmid":"33324564","id":"PMC_33324564","title":"Sintilimab: A Promising Anti-Tumor PD-1 Antibody.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33324564","citation_count":121,"is_preprint":false},{"pmid":"26317459","id":"PMC_26317459","title":"PD-1 Blockers.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26317459","citation_count":120,"is_preprint":false},{"pmid":"29311378","id":"PMC_29311378","title":"Inhibitors of the PD-1 Pathway in Tumor Therapy.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29311378","citation_count":117,"is_preprint":false},{"pmid":"29352857","id":"PMC_29352857","title":"Combining chemotherapy with PD-1 blockade in NSCLC.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29352857","citation_count":115,"is_preprint":false},{"pmid":"22198819","id":"PMC_22198819","title":"Role of PD-1 in HIV pathogenesis and as target for therapy.","date":"2012","source":"Current HIV/AIDS reports","url":"https://pubmed.ncbi.nlm.nih.gov/22198819","citation_count":111,"is_preprint":false},{"pmid":"37059712","id":"PMC_37059712","title":"CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37059712","citation_count":108,"is_preprint":false},{"pmid":"29156447","id":"PMC_29156447","title":"PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29156447","citation_count":107,"is_preprint":false},{"pmid":"24955707","id":"PMC_24955707","title":"PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.","date":"2014","source":"Cancer control : journal of the Moffitt Cancer Center","url":"https://pubmed.ncbi.nlm.nih.gov/24955707","citation_count":105,"is_preprint":false},{"pmid":"24359606","id":"PMC_24359606","title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).","date":"2014","source":"Clinical neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/24359606","citation_count":101,"is_preprint":false},{"pmid":"27683578","id":"PMC_27683578","title":"Features of Memory-Like and PD-1(+) Human NK Cell Subsets.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27683578","citation_count":101,"is_preprint":false},{"pmid":"29260623","id":"PMC_29260623","title":"PD-1/PD-L1 in disease.","date":"2018","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/29260623","citation_count":97,"is_preprint":false},{"pmid":"34183838","id":"PMC_34183838","title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child.","date":"2021","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34183838","citation_count":97,"is_preprint":false},{"pmid":"24975127","id":"PMC_24975127","title":"PD-1 regulates extrathymic regulatory T-cell differentiation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24975127","citation_count":93,"is_preprint":false},{"pmid":"23582509","id":"PMC_23582509","title":"Manipulating the PD-1 pathway to improve immunity.","date":"2013","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23582509","citation_count":89,"is_preprint":false},{"pmid":"16227150","id":"PMC_16227150","title":"PD-1/PD-L pathway and autoimmunity.","date":"2005","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/16227150","citation_count":85,"is_preprint":false},{"pmid":"30396745","id":"PMC_30396745","title":"PD-1 immunobiology in systemic lupus erythematosus.","date":"2018","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30396745","citation_count":80,"is_preprint":false},{"pmid":"20433954","id":"PMC_20433954","title":"PD-1, gender, and autoimmunity.","date":"2010","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20433954","citation_count":79,"is_preprint":false},{"pmid":"37208329","id":"PMC_37208329","title":"ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37208329","citation_count":76,"is_preprint":false},{"pmid":"30862448","id":"PMC_30862448","title":"Inflammatory myopathy associated with PD-1 inhibitors.","date":"2019","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30862448","citation_count":76,"is_preprint":false},{"pmid":"33063473","id":"PMC_33063473","title":"N-glycosylation of PD-1 promotes binding of camrelizumab.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33063473","citation_count":73,"is_preprint":false},{"pmid":"25098286","id":"PMC_25098286","title":"PD-1 as an immune modulatory receptor.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/25098286","citation_count":71,"is_preprint":false},{"pmid":"33109719","id":"PMC_33109719","title":"KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33109719","citation_count":70,"is_preprint":false},{"pmid":"26843495","id":"PMC_26843495","title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.","date":"2016","source":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","url":"https://pubmed.ncbi.nlm.nih.gov/26843495","citation_count":69,"is_preprint":false},{"pmid":"35968783","id":"PMC_35968783","title":"Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35968783","citation_count":69,"is_preprint":false},{"pmid":"33980853","id":"PMC_33980853","title":"PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33980853","citation_count":67,"is_preprint":false},{"pmid":"30952980","id":"PMC_30952980","title":"Depletion of PD-1-positive cells ameliorates autoimmune disease.","date":"2019","source":"Nature biomedical engineering","url":"https://pubmed.ncbi.nlm.nih.gov/30952980","citation_count":66,"is_preprint":false},{"pmid":"26864303","id":"PMC_26864303","title":"Basics of PD-1 in self-tolerance, infection, and cancer immunity.","date":"2016","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26864303","citation_count":65,"is_preprint":false},{"pmid":"25685857","id":"PMC_25685857","title":"Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.","date":"2015","source":"Drugs of today (Barcelona, Spain : 1998)","url":"https://pubmed.ncbi.nlm.nih.gov/25685857","citation_count":63,"is_preprint":false},{"pmid":"37344588","id":"PMC_37344588","title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37344588","citation_count":62,"is_preprint":false},{"pmid":"25011996","id":"PMC_25011996","title":"Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.","date":"2014","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25011996","citation_count":59,"is_preprint":false},{"pmid":"38401888","id":"PMC_38401888","title":"PD-1 regulation in immune homeostasis and immunotherapy.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38401888","citation_count":57,"is_preprint":false},{"pmid":"25625924","id":"PMC_25625924","title":"PD-1 and PD-L1 antibodies for melanoma.","date":"2014","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25625924","citation_count":53,"is_preprint":false},{"pmid":"23548749","id":"PMC_23548749","title":"PD-1 coinhibitory signals: the link between pathogenesis and protection.","date":"2013","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23548749","citation_count":52,"is_preprint":false},{"pmid":"32492969","id":"PMC_32492969","title":"PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32492969","citation_count":42,"is_preprint":false},{"pmid":"25965365","id":"PMC_25965365","title":"Anti-PD-1 therapy in melanoma.","date":"2015","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25965365","citation_count":41,"is_preprint":false},{"pmid":"32554931","id":"PMC_32554931","title":"Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32554931","citation_count":41,"is_preprint":false},{"pmid":"32084380","id":"PMC_32084380","title":"PD-1/PD-L1 in cardiovascular disease.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32084380","citation_count":39,"is_preprint":false},{"pmid":"35756927","id":"PMC_35756927","title":"PD-1/PD-L Axis in Neuroinflammation: New Insights.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35756927","citation_count":39,"is_preprint":false},{"pmid":"29428449","id":"PMC_29428449","title":"PD-1 /PD-L1 checkpoint in hematological malignancies.","date":"2018","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/29428449","citation_count":38,"is_preprint":false},{"pmid":"29360722","id":"PMC_29360722","title":"Clinical Development of PD-1 in Advanced Melanoma.","date":"2018","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/29360722","citation_count":38,"is_preprint":false},{"pmid":"33905818","id":"PMC_33905818","title":"PD-1 signaling pathway in sepsis: Does it have a future?","date":"2021","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/33905818","citation_count":37,"is_preprint":false},{"pmid":"34581778","id":"PMC_34581778","title":"PD-1 inhibition in advanced myeloproliferative neoplasms.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34581778","citation_count":36,"is_preprint":false},{"pmid":"31681606","id":"PMC_31681606","title":"The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31681606","citation_count":35,"is_preprint":false},{"pmid":"32497624","id":"PMC_32497624","title":"Regulation of PD-1 in T cells for cancer immunotherapy.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32497624","citation_count":35,"is_preprint":false},{"pmid":"33738533","id":"PMC_33738533","title":"Transcriptional and epigenetic regulation of PD-1 expression.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33738533","citation_count":34,"is_preprint":false},{"pmid":"28643044","id":"PMC_28643044","title":"PD-1 signaling and inhibition in AML and MDS.","date":"2017","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28643044","citation_count":33,"is_preprint":false},{"pmid":"38457513","id":"PMC_38457513","title":"Transmembrane domain-driven PD-1 dimers mediate T cell inhibition.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38457513","citation_count":32,"is_preprint":false},{"pmid":"32334916","id":"PMC_32334916","title":"The PD-1/PD-L pathway in rheumatic diseases.","date":"2020","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/32334916","citation_count":31,"is_preprint":false},{"pmid":"36649072","id":"PMC_36649072","title":"Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36649072","citation_count":30,"is_preprint":false},{"pmid":"31920637","id":"PMC_31920637","title":"PD-1 Inhibitors in the Advanced Esophageal Cancer.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31920637","citation_count":29,"is_preprint":false},{"pmid":"35640711","id":"PMC_35640711","title":"Strategies for developing PD-1 inhibitors and future directions.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35640711","citation_count":26,"is_preprint":false},{"pmid":"31441370","id":"PMC_31441370","title":"Modulation of PDCD1 exon 3 splicing.","date":"2019","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/31441370","citation_count":26,"is_preprint":false},{"pmid":"33608256","id":"PMC_33608256","title":"DGKA Mediates Resistance to PD-1 Blockade.","date":"2021","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33608256","citation_count":26,"is_preprint":false},{"pmid":"35911672","id":"PMC_35911672","title":"Combination Approaches to Target PD-1 Signaling in Cancer.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35911672","citation_count":26,"is_preprint":false},{"pmid":"30808044","id":"PMC_30808044","title":"PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis.","date":"2019","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/30808044","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43519,"output_tokens":5419,"usd":0.105921,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13840,"output_tokens":4950,"usd":0.096475,"stage2_stop_reason":"end_turn"},"total_usd":0.202396,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"PD-1 delivers inhibitory signals by interacting with its ligands PD-L1 and PD-L2; additionally, B7-1 was identified as a binding partner for PD-L1, revealing an inhibitory bidirectional interaction between PD-L1 and B7-1 that regulates T cell activation and tolerance.\",\n      \"method\": \"Binding partner identification; functional immunological assays in T cells and mouse models\",\n      \"journal\": \"Annual review of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — findings independently replicated across multiple labs and summarized across extensive experimental work including co-receptor binding and mouse knockout models\",\n      \"pmids\": [\"18173375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PD-1 negatively regulates antigen receptor signaling by recruiting the protein tyrosine phosphatase SHP-2 upon interacting with either PD-L1 or PD-L2.\",\n      \"method\": \"Biochemical signaling assays; phosphatase recruitment studies\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — SHP-2 recruitment mechanism replicated across multiple labs; mechanistic consensus in the field\",\n      \"pmids\": [\"17606980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Tumour-associated macrophages (TAMs) express PD-1, and PD-1 expression on TAMs correlates negatively with phagocytic potency against tumour cells. Blockade of PD-1/PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth, and lengthens survival in mouse cancer models in a macrophage-dependent fashion.\",\n      \"method\": \"Flow cytometry of mouse and human TAMs; in vivo PD-1/PD-L1 blockade in mouse cancer models; macrophage depletion experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in mouse and human samples with macrophage-specific depletion validation\",\n      \"pmids\": [\"28514441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PD-1 is extensively N-glycosylated in T cells; glycosylation is critical for PD-1 protein stability and cell surface localization. Glycosylation at the N58 site is essential for mediating PD-1 interaction with PD-L1. TCR activation alters the intensities of specific PD-1 glycoforms.\",\n      \"method\": \"Glycosylation assays; mutagenesis of N-glycosylation sites (N58 and others); cell surface localization studies; PD-L1 binding assays with glycosylation-deficient PD-1\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of specific glycosylation sites combined with binding assays and localization studies in a single study; independently corroborated by EMBO Reports paper (PMID 33063473)\",\n      \"pmids\": [\"32156778\", \"33063473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"N-glycosylation of asparagine 58 (N58) of PD-1 promotes the interaction with the anti-PD-1 antibody camrelizumab. Crystal structure of the camrelizumab/PD-1 complex shows camrelizumab primarily uses its heavy chain to bind PD-1 while the light chain sterically inhibits PD-L1 binding. Non-glycosylated PD-1 shows substantially decreased binding affinity for camrelizumab.\",\n      \"method\": \"Crystal structure of camrelizumab/PD-1 complex; binding affinity assays with glycosylated vs. non-glycosylated PD-1; N-glycan composition analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional validation (binding assays), single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"33063473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PD-1 signaling suppresses TCR-CD8 cooperativity during T cell antigen recognition: PD-1/PD-L1 engagement results in smaller T cell spreading area, fewer molecular bonds formed, and shorter bond lifetimes of T cell interaction with peptide-MHC, in a manner dependent on SHP phosphatases and Leukocyte C-terminal Src kinase (Lck). PD-1 disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction and prevents CD8 from augmenting antigen recognition.\",\n      \"method\": \"Biophysical force measurements; quantitative imaging of T cell-pMHC interactions; SHP inhibition and Lck perturbation experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biophysical reconstitution with multiple orthogonal methods including force measurements and pharmacological dissection of SHP/Lck dependence\",\n      \"pmids\": [\"33980853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PD-1 and its ligands form dimers as a consequence of transmembrane domain interactions. Propensity for dimerization correlates with the ability of PD-1 to inhibit immune responses, antitumor immunity, cytotoxic T cell function, and autoimmune tissue destruction.\",\n      \"method\": \"Biochemical dimerization assays; transmembrane domain mutational analysis; functional T cell assays; in vivo mouse models of antitumor immunity and autoimmunity\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — transmembrane domain mutagenesis linked to functional outcomes in multiple experimental systems\",\n      \"pmids\": [\"38457513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"USP5 is a deubiquitinase for PD-1 that interacts with PD-1 and promotes its deubiquitination and stabilization. ERK phosphorylates PD-1 at Thr234, which promotes PD-1 interaction with USP5. Conditional T cell-specific knockout of Usp5 increases effector cytokine production and retards tumor growth in mice.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; phosphorylation site mutagenesis (Thr234); conditional Usp5 knockout mice; in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, in vitro ubiquitination/deubiquitination assays, site-directed mutagenesis, and in vivo KO with defined phenotype in a single study\",\n      \"pmids\": [\"37208329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KLHL22, an adaptor of the Cul3-based E3 ubiquitin ligase, is a major PD-1-associated protein that mediates ubiquitination and degradation of PD-1 before its transport to the cell surface. KLHL22 deficiency leads to overaccumulation of PD-1, suppressing antitumor T cell responses.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; KLHL22 knockout/knockdown; flow cytometry of surface PD-1; in vivo tumor models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay, KO with surface localization and tumor phenotype readouts\",\n      \"pmids\": [\"33109719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NF-κB regulates PD-1 expression in macrophages. An NF-κB binding site located upstream of the PDCD1 gene in conserved region C is required for NF-κB-dependent PD-1 gene activation in macrophages stimulated with LPS. Chromatin immunoprecipitation showed NF-κB p65 binding to this region. In CD4 T cells, PD-1 induction requires NFAT (blocked by cyclosporin A); in macrophages, LPS-induced PD-1 expression is cyclosporin A-insensitive.\",\n      \"method\": \"NF-κB binding site deletion/mutagenesis; chromatin immunoprecipitation (ChIP); cyclosporin A pharmacological inhibition; stimulation of primary macrophages and T cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter mutagenesis combined with ChIP and pharmacological dissection of signaling pathways\",\n      \"pmids\": [\"25810391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PD-1 engagement by its ligands inhibits T cell proliferation, cytokine production, and cytolytic function by inhibiting membrane-proximal T cell signaling events, in a mechanism distinct from CTLA-4 (which targets more downstream signaling pathways). PD-1 ligation inhibits TCR proximal signaling via phosphatase recruitment.\",\n      \"method\": \"Primary T cell signaling assays; pharmacological inhibition; comparison with CTLA-4 signaling\",\n      \"journal\": \"Cancer journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — review summarizing signaling data from primary T cells; single lab perspective without direct experimental novelty reported in this paper\",\n      \"pmids\": [\"25098287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PD-1 is dispensable for thymic T regulatory (Treg) cell development and suppressive function, but is critical for extrathymic differentiation of peripherally induced Treg (pTreg) cells in vivo. In PD-1-deficient mice, conventional CD4+ T cells showed markedly diminished differentiation into pTreg cells across three different in vivo experimental settings.\",\n      \"method\": \"PD-1-deficient mice; in vivo and in vitro Treg differentiation assays; suppression assays with PD-1−/− Tregs\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PD-1 KO mice with multiple independent in vivo experimental settings and in vitro functional assays\",\n      \"pmids\": [\"24975127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In a patient with inherited complete PD-1 deficiency, leukocytes did not express PD-1 or respond to PD-1-mediated suppression. The patient had depletion of Vδ2+ γδ T, mucosal-associated invariant T (MAIT), and CD56bright NK lymphocytes, with other T cell dysfunction resulting in reduced IFN-γ production upon mycobacterial stimuli and susceptibility to tuberculosis. Expansion of RORγT+ CD4-CD8- double-negative αβ T cells driven by excessive STAT3-activating cytokines (IL-6, IL-23) led to lymphoproliferative autoimmunity.\",\n      \"method\": \"Human genetics (inherited PDCD1 loss-of-function); immunophenotyping; functional T cell assays; cytokine measurement; transcription factor analysis\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human inborn error of immunity with comprehensive mechanistic characterization across multiple immune lineages\",\n      \"pmids\": [\"34183838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MATR3 is a splicing activator for PDCD1 exon 3 splicing, operating through binding to the ESE3b splicing enhancer in exon 3. MATR3's splicing-stimulatory activity is counteracted by an RNA secondary structure around ESE3b and an RNA helicase DDX5. Two splicing enhancers (ESE3a and ESE3b) in exon 3 regulate alternative splicing of PDCD1 to generate the exon 3-skipped isoform PD-1Δ3.\",\n      \"method\": \"Minigene splicing assays; deletion analysis; mutagenesis; RNA-affinity chromatography; mass spectrometry; MATR3 depletion and overexpression\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution (RNA affinity chromatography), mutagenesis, MS identification of binding proteins, and functional splicing assays\",\n      \"pmids\": [\"31441370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In obesity, type I inflammatory cytokines and obesity-linked molecules (IFN-γ, TNF, leptin, insulin, palmitate) induce macrophage PD-1 expression in an mTORC1- and glycolysis-dependent manner. PD-1 then provides negative feedback to TAMs, suppressing glycolysis, phagocytosis, and T cell stimulatory potential. Myeloid-specific PD-1 deficiency slows tumor growth, enhances TAM glycolysis and antigen-presentation, and increases CD8+ T cell activity.\",\n      \"method\": \"In vitro macrophage stimulation assays; mTORC1 inhibition; myeloid-specific PD-1 KO mice; glycolysis measurements; flow cytometry of MHC/CD86 expression and T cell activation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — myeloid-specific KO with multiple mechanistic readouts (glycolysis, phagocytosis, antigen presentation) and pharmacological dissection of mTORC1 pathway\",\n      \"pmids\": [\"38867043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PD-1 maintains peripheral CD8 T cell tolerance in skin by preventing tissue-infiltrating antigen-specific effector CD8 T cells from acquiring a fully pathogenic differentiation state, secreting effector molecules, and gaining access to epidermal antigen-expressing cells. In the absence of PD-1, epidermal antigen-expressing cells were eliminated by CD8 T cells, causing local pathology.\",\n      \"method\": \"Mouse model with skin-specific T cell antigen expression; PD-1 KO; transcriptomic analysis; CD8 T cell functional assays; analysis of human skin biopsies from lichenoid irAE patients\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mouse genetic model with defined antigen specificity and PD-1 KO, validated with human clinical biopsy transcriptomics\",\n      \"pmids\": [\"37344588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PD-1 signaling in podocytes contributes to kidney aging: increased PD-1 expression in aged podocytes promotes a senescence-associated secretory phenotype (SASP) and reduces cell survival in vitro. Anti-PD-1 antibody treatment in aged mice improved the aging phenotype in kidney and liver, specifically extending podocyte lifespan in the glomerulus.\",\n      \"method\": \"In vitro podocyte PD-1 signaling assays; anti-PD-1 antibody treatment of aged mice; transcriptomic and immunohistochemistry studies; focal segmental glomerulosclerosis (FSGS) mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic studies plus in vivo KO/blockade in two independent mouse models; non-canonical cell type (podocytes)\",\n      \"pmids\": [\"35968783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PD-L1+ senescent cells are resistant to CD8+ T cell immune surveillance, whereas PD-L1- senescent cells are sensitive. PD-1 antibody administration to naturally ageing or NASH-model mice reduces total p16+ senescent cells and the PD-L1+ senescent cell population in an activated CD8+ T cell-dependent manner.\",\n      \"method\": \"Single-cell analysis of p16+ cells in vivo; PD-1 antibody treatment of aged and disease mouse models; CD8+ T cell depletion experiments; flow cytometry\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CD8+ T cell depletion epistasis experiment establishes mechanism; replicated in multiple in vivo models\",\n      \"pmids\": [\"36323784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A proliferative CD8+ T cell subset that responds to PD-1 blockade during chronic LCMV infection is characterized by PD-1 expression alongside costimulatory molecules (ICOS, CD28), a TCF1-dependent gene signature related to memory precursors and stem cells, and exclusive residence in lymphoid tissue T cell zones. This subset undergoes self-renewal and differentiates into terminally exhausted CD8+ T cells. TCF1 has a cell-intrinsic and essential role in generating this subset.\",\n      \"method\": \"Mouse chronic LCMV infection model; PD-1 blockade; transcriptomic profiling; TCF1-deficient mice; cell fate tracking; tissue localization studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — TCF1 genetic KO with cell fate tracking and transcriptomics in a well-controlled chronic infection model\",\n      \"pmids\": [\"27501248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Pre-existing CD8+ T cells at the invasive tumor margin that express PD-1, in close proximity to PD-L1-expressing cells, predict response to anti-PD-1 therapy. Responding patients showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic tumor reduction, consistent with PD-1/PD-L1-mediated adaptive immune resistance as the mechanism of suppression.\",\n      \"method\": \"Quantitative immunohistochemistry; quantitative multiplex immunofluorescence; next-generation TCR sequencing; serial tumor biopsies before and during pembrolizumab therapy\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — correlative tissue analysis in human patients with serial biopsies; consistent with mechanism but observational rather than experimental\",\n      \"pmids\": [\"25428505\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PD-1 (PDCD1) is an inducible inhibitory receptor on T cells (and other immune cells including macrophages) that, upon engagement by PD-L1 or PD-L2, recruits the tyrosine phosphatase SHP-2 to dephosphorylate proximal TCR signaling components, disrupts cooperative TCR-pMHC-CD8 trimolecular antigen recognition, suppresses T cell proliferation/cytokine production/cytolysis, and promotes peripheral tolerance; its surface expression and stability are regulated by N-glycosylation (critical for PD-L1 binding at N58), ubiquitination/deubiquitination (via KLHL22/Cul3 E3 ligase for degradation and USP5 deubiquitinase for stabilization downstream of ERK-mediated Thr234 phosphorylation), NF-κB- and NFAT-dependent transcription, and alternative splicing (regulated by MATR3/ESE3b); PD-1 also forms functional transmembrane dimers whose dimerization propensity correlates with inhibitory potency, and beyond T cells, PD-1 on macrophages suppresses phagocytosis and antigen presentation via mTORC1/glycolysis-dependent feedback, while PD-1 on podocytes drives senescence-associated phenotypes during kidney aging.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PDCD1 (PD-1) is an inducible inhibitory immune receptor that, upon engagement by its ligands PD-L1 and PD-L2, restrains antigen-receptor signaling to enforce peripheral tolerance and limit antiretumor and antimicrobial immunity [#0, #10]. Mechanistically, ligand-bound PD-1 recruits the tyrosine phosphatase SHP-2 to dephosphorylate membrane-proximal TCR signaling components, thereby inhibiting T cell proliferation, cytokine production, and cytolytic function in a manner distinct from CTLA-4 [#1, #10]; biophysically, this disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction, reducing T cell spreading and bond lifetimes in an SHP- and Lck-dependent fashion [#5]. PD-1 surface expression and signaling output are tightly tuned: transcription is driven by NFAT in CD4 T cells and by NF-\\u03baB in macrophages [#9]; N-glycosylation, particularly at N58, controls protein stability, surface localization, and PD-L1 binding [#3]; and surface abundance is set by competing ubiquitination via the KLHL22/Cul3 E3 ligase that degrades PD-1 before surface transport and deubiquitination/stabilization by USP5 downstream of ERK-mediated Thr234 phosphorylation [#7, #8]. PD-1 also forms transmembrane-domain-mediated dimers whose dimerization propensity correlates with inhibitory potency [#6], and its exon 3 alternative splicing is governed by MATR3 acting through the ESE3b enhancer [#13]. Physiologically, PD-1 supports peripheral induced Treg differentiation and CD8 T cell tolerance in tissues such as skin [#11, #15], and shapes the TCF1-dependent stem-like CD8 T cell subset that responds to PD-1 blockade during chronic infection [#18]. Inherited complete PD-1 deficiency in humans causes multilineage lymphocyte dysfunction, susceptibility to tuberculosis, and STAT3-cytokine-driven lymphoproliferative autoimmunity, establishing its non-redundant tolerogenic role [#12]. Beyond T cells, PD-1 is expressed on tumor-associated macrophages where it suppresses phagocytosis, glycolysis, and antigen presentation through mTORC1-dependent feedback [#2, #14], and on aged podocytes where it drives senescence-associated phenotypes [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the proximal biochemical mechanism of PD-1 inhibition by showing ligand engagement recruits the phosphatase SHP-2 to antigen-receptor signaling machinery.\",\n      \"evidence\": \"Biochemical phosphatase recruitment assays following PD-L1/PD-L2 engagement\",\n      \"pmids\": [\"17606980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which TCR substrates are dephosphorylated\", \"SHP-1 versus SHP-2 contributions not delineated here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the receptor-ligand topology of the pathway, identifying PD-L1 and PD-L2 as PD-1 ligands and an additional inhibitory PD-L1/B7-1 axis regulating tolerance.\",\n      \"evidence\": \"Binding partner identification and functional immunological assays in T cells and mouse models\",\n      \"pmids\": [\"18173375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of each ligand interaction not quantified\", \"Does not address cell-type-specific ligand usage\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Distinguished PD-1 from CTLA-4 mechanistically by localizing PD-1 inhibition to membrane-proximal TCR events, and defined PD-1 as required for peripheral but not thymic Treg differentiation.\",\n      \"evidence\": \"Primary T cell signaling assays and PD-1-deficient mouse Treg differentiation/suppression assays\",\n      \"pmids\": [\"25098287\", \"24975127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling comparison drawn from review-level synthesis\", \"Molecular link between PD-1 signaling and pTreg fate not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved cell-type-specific transcriptional control of PDCD1, showing NF-\\u03baB drives macrophage expression while NFAT drives T cell induction.\",\n      \"evidence\": \"Promoter mutagenesis, ChIP for NF-\\u03baB p65, and cyclosporin A dissection in primary macrophages and T cells\",\n      \"pmids\": [\"25810391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of regulatory elements not mapped\", \"Does not address chromatin state or enhancer dynamics during exhaustion\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified the cellular target of PD-1 blockade as a TCF1-dependent stem-like CD8 T cell subset that self-renews and seeds terminally exhausted cells.\",\n      \"evidence\": \"Chronic LCMV mouse model, PD-1 blockade, transcriptomics, TCF1-deficient mice, and cell fate tracking\",\n      \"pmids\": [\"27501248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular signaling from PD-1 to TCF1 program not established\", \"Human correlate not tested in this study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended PD-1 function beyond T cells by demonstrating macrophage PD-1 restrains tumor-cell phagocytosis, with blockade acting in a macrophage-dependent manner.\",\n      \"evidence\": \"Flow cytometry of mouse/human TAMs, in vivo PD-1/PD-L1 blockade, and macrophage depletion\",\n      \"pmids\": [\"28514441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway downstream of macrophage PD-1 not defined in this study\", \"Does not separate direct macrophage effect from T cell crosstalk fully\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered post-transcriptional control of PD-1 by defining MATR3 as a splicing activator for PDCD1 exon 3 acting through the ESE3b enhancer, counteracted by RNA structure and DDX5.\",\n      \"evidence\": \"Minigene splicing assays, RNA-affinity chromatography, mass spectrometry, and MATR3 depletion/overexpression\",\n      \"pmids\": [\"31441370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the PD-1\\u03943 isoform in vivo not established\", \"Physiological signals that tune splicing not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established that N-glycosylation controls PD-1 stability, surface localization, and ligand/antibody binding, with N58 critical for PD-L1 and camrelizumab engagement.\",\n      \"evidence\": \"Glycosylation-site mutagenesis, binding assays, surface localization studies, and a camrelizumab/PD-1 crystal structure\",\n      \"pmids\": [\"32156778\", \"33063473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes generating specific glycoforms not identified\", \"Link between TCR-induced glycoform changes and inhibitory output not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a degradative arm of PD-1 surface control, showing the KLHL22/Cul3 E3 ligase ubiquitinates PD-1 before surface transport to limit its accumulation.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, KLHL22 knockout/knockdown, surface PD-1 flow cytometry, and tumor models\",\n      \"pmids\": [\"33109719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subcellular site of ubiquitination not precisely localized\", \"Signals regulating KLHL22 activity unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided biophysical mechanism showing PD-1 disrupts cooperative TCR-pMHC-CD8 trimolecular antigen recognition in an SHP- and Lck-dependent manner.\",\n      \"evidence\": \"Biophysical force measurements, quantitative imaging of T cell-pMHC interactions, and SHP/Lck perturbation\",\n      \"pmids\": [\"33980853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphatase substrate at the CD8 coreceptor not identified\", \"In vivo relevance of altered bond lifetimes not measured\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated the non-redundant human role of PD-1 through an inherited complete deficiency causing multilineage lymphocyte loss, tuberculosis susceptibility, and STAT3-cytokine-driven autoimmunity.\",\n      \"evidence\": \"Human genetics of PDCD1 loss-of-function with immunophenotyping, functional T cell and cytokine assays\",\n      \"pmids\": [\"34183838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-patient inborn error limits generalization\", \"Mechanistic basis for selective lineage depletion not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected PD-1 to senescence biology, showing PD-L1+ senescent cells evade CD8 surveillance and PD-1 blockade clears senescent cells, while PD-1 in podocytes drives senescence-associated phenotypes during aging.\",\n      \"evidence\": \"Single-cell p16 analysis with CD8 depletion epistasis; in vitro podocyte signaling plus anti-PD-1 treatment in aged/FSGS mouse models\",\n      \"pmids\": [\"36323784\", \"35968783\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Podocyte-intrinsic PD-1 signaling pathway not fully defined\", \"Whether senescent-cell clearance is purely T cell-extrinsic to podocyte PD-1 unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed PD-1 enforces tissue tolerance by preventing antigen-specific effector CD8 T cells from acquiring a fully pathogenic state in skin, with human irAE relevance.\",\n      \"evidence\": \"Skin-antigen mouse model with PD-1 KO, transcriptomics, CD8 functional assays, and human lichenoid irAE biopsy transcriptomics\",\n      \"pmids\": [\"37344588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular checkpoint within the differentiation trajectory not pinpointed\", \"Generalizability to non-skin tissues not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a stabilizing arm of PD-1 abundance control, showing ERK-mediated Thr234 phosphorylation recruits USP5 to deubiquitinate and stabilize PD-1.\",\n      \"evidence\": \"Reciprocal Co-IP, ubiquitination assays, Thr234 mutagenesis, and T cell-specific Usp5 knockout tumor models\",\n      \"pmids\": [\"37208329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between USP5 stabilization and KLHL22 degradation not integrated\", \"Upstream triggers of ERK-Thr234 phosphorylation not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined PD-1 dimerization and macrophage metabolic feedback as determinants of inhibitory potency, linking transmembrane-domain dimerization to function and mTORC1/glycolysis to macrophage PD-1 induction.\",\n      \"evidence\": \"Transmembrane-domain mutagenesis with functional T cell/tumor/autoimmunity assays; macrophage stimulation, mTORC1 inhibition, and myeloid-specific PD-1 KO with glycolysis/antigen-presentation readouts\",\n      \"pmids\": [\"38457513\", \"38867043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dimer assembly not solved\", \"How dimerization mechanistically amplifies SHP recruitment not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing ubiquitination/deubiquitination, glycosylation, dimerization, and splicing inputs are integrated to set PD-1 inhibitory output in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model linking surface-abundance control to signaling strength\", \"Non-T-cell PD-1 signaling cascades (macrophage, podocyte) incompletely mapped\", \"Direct phosphatase substrate set not fully enumerated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 10, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 8, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 10, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 5, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 7, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD274\", \"PDCD1LG2\", \"PTPN11\", \"USP5\", \"KLHL22\", \"MATR3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}